Body composition, endocrine and metabolic profiles in adults with Prader-Willi syndrome

Growth Hormone and IGF Research

Volumn 20, Issue 3, 2010, Pages 179-184

  Sode Carlsen, Rasmus ^a   Farholt, Stense ^a   Rabben, Kai Fr ^b   Bollerslev, Jens ^a   Schreiner, Thomas ^a   Jurik, Anne Grethe ^a   Christiansen, Jens Sandahl ^a   Höybye, Charlotte ^c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Department of Endocrinology ^*

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adults; Body composition; Metabolism; PWS

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SOMATOMEDIN C; THYROTROPIN; THYROXINE; TRIACYLGLYCEROL;

ABDOMINAL SUBCUTANEOUS FAT; ADOLESCENT; ADULT; ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; BODY MASS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HORMONE DETERMINATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INTRAABDOMINAL FAT; MALE; MUSCLE MASS; ORAL GLUCOSE TOLERANCE TEST; PRADER WILLI SYNDROME; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; BODY COMPOSITION; BODY WEIGHTS AND MEASURES; ENDOCRINE SYSTEM; FEMALE; HUMAN GROWTH HORMONE; HUMANS; HYPOGONADISM; INTRA-ABDOMINAL FAT; LIPIDS; MALE; METABOLOME; MIDDLE AGED; PRADER-WILLI SYNDROME; SUBCUTANEOUS FAT; YOUNG ADULT;

EID: 77953081498     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2009.12.004     Document Type: Article

References (33)

1. Gunay-Aygun M., Schwartz S., Heeger S., O'Riordan M.A., Cassidy S.B. The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria. Pediatrics 2001, 108:E92.
2. Holm V.A., Cassidy S.B., Butler M.G., et al. Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics 1993, 91:398-402.
3. Burman P., Ritzen E.M., Lindgren A.C. Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH. Endocr. Rev. 2001, 22:787-799.
4. Goldstone A.P. Prader-Willi syndrome: advances in genetics, pathophysiology and treatment. Trends Endocrinol. Metab. 2004, 15:12-20.
5. Brambilla P., Bosio L., Manzoni P., Pietrobelli A., Beccaria L., Chiumello G. Peculiar body composition in patients with Prader-Labhart-Willi syndrome. Am. J. Clin. Nutr. 1997, 65:1369-1374.
6. Goldstone A.P., Thomas E.L., Brynes A.E., et al. Visceral adipose tissue and metabolic complications of obesity are reduced in Prader-Willi syndrome female adults: evidence for novel influences on body fat distribution. J. Clin. Endocrinol. Metab. 2001, 86:4330-4338.
7. Hoybye C., Hilding A., Jacobsson H., Thoren M. Metabolic profile and body composition in adults with Prader-Willi syndrome and severe obesity. J. Clin. Endocrinol. Metab. 2002, 87:3590-3597.
8. Theodoro M.F., Talebizadeh Z., Butler M.G. Body composition and fatness patterns in Prader-Willi syndrome: comparison with simple obesity. Obesity (Silver Spring) 2006, 14:1685-1690.
9. van Mil E.G., Westerterp K.R., Kester A.D., et al. Activity related energy expenditure in children and adolescents with Prader-Willi syndrome. Int. J. Obes. Relat. Metab. Disord. 2000, 24:429-434.
10. Butler M.G., Theodoro M.F., Bittel D.C., Donnelly J.E. Energy expenditure and physical activity in Prader-Willi syndrome: comparison with obese subjects. Am. J. Med. Genet. A 2007, 143:449-459.
11. Goldstone A.P., Brynes A.E., Thomas E.L., et al. Resting metabolic rate, plasma leptin concentrations, leptin receptor expression, and adipose tissue measured by whole-body magnetic resonance imaging in women with Prader-Willi syndrome. Am. J. Clin. Nutr. 2002, 75:468-475.
12. Whittington J.E., Holland A.J., Webb T., Butler J., Clarke D., Boer H. Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK health region. J. Med. Genet. 2001, 38:792-798.
13. Graham I., Atar D., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice. Full text. Fourth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur. J. Cardiovasc. Prev. Rehabil. 2007, 14(Suppl. 2):S1-113.
14. Price G.M., Uauy R., Breeze E., Bulpitt C.J., Fletcher A.E. Weight, shape, and mortality risk in older persons: elevated waist-hip ratio, not high body mass index, is associated with a greater risk of death. Am. J. Clin. Nutr. 2006, 84:449-460.
15. Jensen M.D., Kanaley J.A., Reed J.E., Sheedy P.F. Measurement of abdominal and visceral fat with computed tomography and dual-energy x-ray absorptiometry. Am. J. Clin. Nutr. 1995, 61:274-278.
16. Norrelund H., Hove K.Y., Brems-Dalgaard E., et al. Muscle mass and function in thyrotoxic patients before and during medical treatment. Clin. Endocrinol. (Oxf) 1999, 51:693-699.
17. Frystyk J., Dinesen B., Orskov H. Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Regul. 1995, 5:169-176.
18. Whitworth J.A. 2003 World health organization (WHO)/international society of hypertension (ISH) statement on management of hypertension. J. Hypertens. 2003, 21:1983-1992.
19. Diagnosis and classification of diabetes mellitus. Diabetes Care 29(Suppl. 1) (2006) S43-S48.
20. Albareda M., Rodriguez-Espinosa J., Murugo M., de L.A., Corcoy R. Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test. Diabetologia 2000, 43:1507-1511.
21. Bonora E., Kiechl S., Willeit J., et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998, 47:1643-1649.
22. Aimaretti G., Corneli G., Razzore P., et al. Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone+arginine as provocative tests for the diagnosis of GH deficiency in adults. J. Clin. Endocrinol. Metab. 1998, 83:1615-1618.
23. Corneli G., Di S.C., Baldelli R., et al. The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur. J. Endocrinol. 2005, 153:257-264.
24. Gondoni L.A., Vismara L., Marzullo P., Vettor R., Liuzzi A., Grugni G. Growth hormone therapy improves exercise capacity in adult patients with Prader-Willi syndrome. J. Endocrinol. Invest. 2008, 31:765-772.
25. Mogul H.R., Lee P.D., Whitman B.Y., et al. Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: results from the United States multicenter trial. J. Clin. Endocrinol. Metab. 2008, 93:1238-1245.
26. Goodpaster B.H., Thaete F.L., Kelley D.E. Thigh adipose tissue distribution is associated with insulin resistance in obesity and in type 2 diabetes mellitus. Am. J. Clin. Nutr. 2000, 71:885-892.
27. Grugni G., Marzullo P., Ragusa L., et al. Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome. Clin. Endocrinol. (Oxf) 2006, 65:492-499.
28. Darzy K.H., Aimaretti G., Wieringa G., Gattamaneni H.R., Ghigo E., Shalet S.M. The usefulness of the combined growth hormone (GH)-releasing hormone and arginine stimulation test in the diagnosis of radiation-induced GH deficiency is dependent on the post-irradiation time interval. J. Clin. Endocrinol. Metab. 2003, 88:95-102.
29. Partsch C.J., Lammer C., Gillessen-Kaesbach G., Pankau R. Adult patients with Prader-Willi syndrome: clinical characteristics, life circumstances and growth hormone secretion. Growth Horm. IGF Res. 2000, 10(Suppl. B):S81-S85.
30. Hoybye C., Frystyk J., Thoren M. The growth hormone-insulin-like growth factor axis in adult patients with Prader Willi syndrome. Growth Horm. IGF Res. 2003, 13:269-274.
31. Hoffman D.M., O'Sullivan A.J. Diagnosis of growth-hormone deficiency in adults. Lancet 1994, 343:1064.
32. Hoybye C., Hilding A., Jacobsson H., Thoren M. Growth hormone treatment improves body composition in adults with Prader-Willi syndrome. Clin. Endocrinol. (Oxf) 2003, 58:653-661.
33. Tchernof A., Despres J.P. Sex steroid hormones, sex hormone-binding globulin, and obesity in men and women. Horm. Metab. Res. 2000, 32:526-536.